01/21/2026
The growing pipeline of lower-cost biosimilar alternatives is reshaping pharmacy spend. 💲 With 35 biosimilars on the way, now is the time to evaluate how these high-value options can lower costs and strengthen your plan strategy.
👉 At ProAct, we’re committed to ensuring your pharmacy benefits remain predictable, affordable, and accessible. Let’s build a smarter, more sustainable plan together. Contact us today to learn how we can help you maximize your savings potential: https://hubs.li/Q03_G_nh0